Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - ASP, Sales Volume by Product Types & Procedures The global biosurgery market will witness a robust CAGR of 5.7%, valued at $15.93 billion in 2021, and expected to appreciate and reach $26.25 billion by 2030, confirms Strategic Market Research. Bio-surgery is a trend that is offering potential business opportunities and attracting investments in research & development. The use of living cells in the treatment of wounds is a practice that is gaining traction as they facilitate faster recovery and improved tissue regeneration in even the most complicated scenarios. It has also been observed that bio-based wound treatment techniques greatly reduce wound scars compared to conventional patches and stitches. Soon it is expected that more companies offering conventional wound healing products will diversify into bio-based wound care products such as patches, wound sealants, and more. Innovative bio-based wound dressing techniques are being developed using materials like porcine collagen, bio-based electro-spun fibers, blood-derived biomaterials, and others. Companies developing these products are also looking to target additional revenue streams, such as treating diabetic foot ulcers, leg ulcers, bedsores, and similar problems. Bio-surgery, a topical treatment known as larva or maggot therapy, is a surgical debridement used for wound healing resistant to antibiotics and treating infections. It has also proven effective for diabetic patients. The biosurgery products contain semi-synthetic, synthetic, or natural materials that help seal surgical incisions and tissue repairs. They control surgical bleeding for various surgical conditions. It comprises of various technologies and surgical techniques meant to diminish intra- and postoperative complications by facilitating hemostasis & tissue sealing. It also finds application in hard tissue regeneration in orthobiologics. According to the National Health Statistics report, approximately 48.3 million surgical and nonsurgical procedures in the U.S. were performed. Nearly 25.7 million procedures were performed in hospitals, and 22.7 million were performed in ambulatory surgery centers. The increased focus on effective blood loss management, growth in the volume of elective surgeries, increased lifestyle disorders & chronic diseases, and rising geriatric population can contribute to an increase in elective surgical procedures globally, which will further augment the growth of the Bio-surgery Market. Market Drivers - Need for effective blood loss management in patients and the rise in the number of surgeries. New products are being developed that are revolutionizing tissue adhesion and repair procedures. In modern wound treatments, fibrin sealants are being used with various applicator technologies to prevent bleeding during the treatment procedure. Companies have developed ready-to-use patches that can apply to dry and wet areas during wound treatment. Accidents have increased the number of surgeries that involve long operating hours, which increased the necessity for effective blood loss management products. As per National Trauma Institute, hemorrhage is responsible for over 35% of pre-hospital deaths and over 40% of deaths within 24 hours of the injury. It led to the growing adoption of biosurgery products over conventional products; hence, the need to control blood loss is one of the major factors driving the biosurgery industry. As per the U.N., the senior population aged 60 and older in 2020 was around 727 million, which is about 12.3 percent of the global population, and by 2050, that will increase to almost 22 percent. Furthermore, as per the World Health Organization, obesity has nearly tripled globally since 1975. In 2020, 39 million children under 5 were overweight or obese. Thus, the geriatric and obese population increase the risk of larger incidence of neurological and orthopedic problems that can lead to biosurgery for treatment thereby driving the growth of the market. Increasing demand for improved surgical care for patients of all ages is one of the drivers of the Biosurgery market's growth. National Library of Medicine report states that about 310 Mn major surgeries are duly performed globally. Around 40-50 million are performed in the U.S., accounting for the highest number of surgeries, and 20 Mn in Europe. Market Restraints – High cost of bio-surgery products and surgical procedures The bio-surgery market is premium priced due to the highly competitive intensity among existing players. The high cost and hospital reimbursement scenario for these products in emerging countries make them unaffordable for the target patient population giving preference to the conventional product during surgeries across emerging countries, which in turn is limiting and restricting the market growth. Due to the costly biosurgery products, conventional procedures like ligature based procedures and sutures are preferred at the time of surgeries among emerging countries. Market Opportunities – Increase in adoption of advanced bio-surgery products in emerging markets With the rising trend of telemedicine, surgeries and the bio-based wound care industry will also get a boost. It is because using these products is relatively easier and can be supervised by a virtual wound care clinic. Most other wound treatment and surgical modalities are complex and require the presence of an expert to perform the procedures. There is a spur to adopt advanced bio-surgery products across emerging countries. The markets in emerging economies are characterized by a large patient base for the target indications like (cardiovascular, gynecological, orthopedic disorders), rising health awareness, rising medical tourism, growing healthcare expenditure & rapidly developing healthcare infrastructure. The cost of medical procedures in emerging countries is significantly less than in developed countries. Moreover, government agencies in these markets are taking initiatives to support their specific healthcare systems, which helps the growth and leverage the opportunities for the biosurgery market. An increase in medical tourism can be a significant opportunity for developing countries such as India, China, Malaysia due to the rise in the costs of healthcare expenditure in developed countries like France, Germany, US, UK. As per the health tourism report, Mexico has become a top medical tourism destination due to its proximity to the U.S., with 40,000 to 80,000 Americans who are senior citizens spend their retirement there with majority of them receiving nursing homes & healthcare services. Market Analysis of different Segmentations Covered in the Report Based on Product Type Bone-Graft Substitutes Demineralized Bone Matrix Synthetic Bone Grafts Bone Morphogenetic Proteins Others Soft-Tissue Attachments Biological Allografts Xenografts Synthetic Hemostatic Agents Thrombin-based Oxidized Regenerated Cellulose-based Combination-based Surgical Sealants and Adhesives Natural/Biological Sealants and Adhesives Fibrin Collagen Gelatin Albumin Others Synthetic and Semi-Synthetic Sealants and Adhesives Peg Hydrogels Cyanoacrylate-Based Sealants and Adhesives Urethane-Based Sealants and Adhesives Others Adhesion Barriers Synthetic Adhesion Barriers Hyaluronic Acid-Based Adhesion Barriers Regenerated Cellulose-Based Adhesion Barriers Peg-Based Adhesion Barriers Ther Synthetic Adhesion Barriers Natural Adhesion Barriers Collagen & Protein Adhesion Barriers Fibrin-Based Adhesion Barriers Staple-Line Reinforcement Agents Based on Surgery Orthopedic General Neurological Cardiovascular Reconstructive Gynecological Urological Thoracic Based on Origin Biological Synthetic Based on End-user Hospitals Ambulatory Surgical Centers Clinics Others Regional Coverage Analysis North America • U.S. • Mexico • Canada • Rest of North America Europe • France • Germany • U.K. • Spain • Italy • Rest of Europe Asia Pacific • China • India • South Korea • Japan • Australia • Rest of APAC LAMEA • Brazil • Saudi Arabia • Uruguay • Argentina • Rest of LAMEA Product Type Analysis & Insights Based on Product Type, the bone graft substitutes segment dominated the overall market with a steady CAGR during the estimated period. Predominant factors such as the rise in use of bone graft proxy products in orthopedic and dental surgeries and the satisfaction offered by bone graft substitute products over conventional autograft products are driving the segment's growth. As per the article" Impact of the COVID-19 Outbreak on Orthopedic Surgery "in 2021, out of 1,330,477 hospital discharges identified in 2020, 99,333 were the orthopedic surgical procedures that accounted for 7.47 percent. Surgery Analysis & Insights Based on Surgery, the General surgery segment dominated the Biosurgery market in 2020, accounting for a robust CAGR of 8.6%. Factors like the rise in technological advancements and the rising adoption of technically advanced surgeries in developing economies are propelling the overall growth of this segment. As per the Estimation of the National Surgical Needs in India 2020, 949 surgeries are performed annually, accounting for 614 surgeries in males and 335 in females. End Users Analysis & Insights Based on End Users, the Hospitals segment accounts for a substantial market share in 2020. Factors such as the exponential rise of hospitals and infrastructural & economic development, especially in emerging countries, and the increasing number of surgical procedures performed in hospital operating rooms are driving the segment's overall growth. As per Stanford health, about 48 million surgeries are being performed each year in hospitals, with cardiovascular diseases having the most significant share, nearly 7.3 million each year in the U.S. Regions Analysis & Insights Based on Regions, North America dominated the market with the largest share in 2020. The highest percentage in the North American region can primarily be attributed to favorable reimbursement policies for biosurgery products, the increasing number of healthcare settings, a highly developed healthcare system, the rise in the number of vendors, the rising prevalence of traumatic injuries, lifestyle disorders and the increasing geriatric population. According to the Rural health information hub, there are more than 46 Mn adults over the age of 65 in the United States, with the count estimated to reach 90 Mn by 2050. 1 in 5 Americans is projected to be older than 65 by 2030. The Asia-Pacific region is the fastest-growing market, expected to grow at a CAGR of 10.2% from 2021 to 2030 due to the senior population surge and rise in sport-related injuries leading to an increase in the demand for biosurgery products. Biosurgery Devices Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 15.93 Billion The revenue forecast in 2030 USD 26.25 Billion Growth rate 5.7% The base year for estimation 2021 Historical data 2017 - 2020 Quantitative units Revenue in USD Billion and CAGR from 2021 to 2030 Report coverage Revenue forecast, , competitive landscape, company ranking, growth factors, and trends Segmentation By Product Type, By Surgery, By Origin, By End User, and By Region. By Product Type Bone-Graft Substitutes, Soft-Tissue Attachments, Hemostatic Agents, Surgical Sealants and Adhesives, Adhesion Barriers, Staple-Line Reinforcement Agents By Surgery Orthopedic, General, Neurological, Cardiovascular, Reconstructive, Gynecological, Urological, and Thoracic By Origin Biological, Synthetic By End-User Hospitals, Ambulatory Surgical Centers, Clinics, and Others By Region North America, Asia Pacific, Europe, and LAMEA Country Scope U.S., Canada, France, U.K., China, Germany, Japan, India, Mexico, South Korea, Brazil, U.A.E., etc. Company Usability Profiles Johnson & Johnson, Baxter International Inc., Medtronic Plc, Becton, Dickinson & Co., B. Braun Melsungen AG, Stryker Corp., Integra Lifesciences Holdings Corp., CSL Ltd., Hemostasis LLC., Pfizer Inc., Cyrolife Inc., Zimmer Biomet, Kuros Biosciences AG ,Orthofix Medical Inc., Smiths & Nephew Plc, ecm biosurgery, Genzyme biosurgery Global Biosurgery Market: Competitive Landscape with detailed Overview The competitive landscape analysis lays down information about the core competitors operating in the worldwide market environment. The comparison is based on key development strategies, new product launches, acquisitions, existing products and technologies advancements, company financials, company strengths and weaknesses, production capacity, global presence, production sites, facilities, market potential, etc. Global Biosurgery Market Competitive Landscape Analysis Johnson & Johnson Baxter International Inc. Medtronic Plc Becton, Dickinson & Co. B. Braun Melsungen AG Stryker Corp. Integra Lifesciences Holdings Corp. CSL Ltd. Hemostasis L.L.C. Pfizer Inc. Cyrolife Inc. Zimmer Biomet Kuros Biosciences AG Orthofix Medical Inc. Smiths & Nephew Plc. ecm biosurgery Genzyme biosurgery Global Biosurgery Market: Recent Developments On September, 2021, Tissue Regenix, a regenerative medical technology firm, announced the launch of DermaPure Meshed and VNEWTM, two-line extensions to the BioSurgery division that utilize Tissue Regenix's unique decellularisation Technology. DermaPure Meshed gives surgeons a customized new option that eradicates time taking manual meshing at the operation theatre, optimizing patient outcomes. VNEWTM that is the pre-shaped & pre cut acellular dermal allograft which is designed for pelvic organ prolapse which is a surgical procedure intended to reconstruct, repair, & reinforce weakened or damaged tissue. On April, 2021, Aroa Biosurgery Limited, a soft tissue regeneration firm, introduced Myriad Morcells, a morselized (powder) version of Myriad Matrix that easily optimizes interaction with irregular wound beds. The new product is provided in a convenient tray for hydration, mixing, pouring and enables rapid vascularization. It helps to build new tissue, leading to faster healing, recovery, and hospital discharge. In the year 2020 - Orthofix Medical, a world renowned medical device company, declared the launch of O GENESIS Graft Delivery System & Allo Quent Structural Allograft Q Pack. The O GENESIS Graft Delivery System is designed with ergonomics. The system enables single-handed delivery and features two streamlined loading options to accommodate a versatile choice of other bone graft materials. The AlloQuent Structural Allografts are the precision machined lumbar and cervical spacers and offer procedure-specific spacers with surgical efficiency in ready-to-use packaging. On February, 2020, Baxter, a global leader in advancing surgical innovation, announced 510 (k) clearance from US FDA for Peri-Strips Dry with Veritas Collagen Matrix product along with Secure Grip staple line reinforcement agent, two times faster to prepare than the previous version staple line reinforcement product. It is indicated for reducing and mitigating the bleeding at the time of bariatric surgeries and various other surgical procedures. Frequently Asked Question About This Report What products have been included in the Biosurgery market report? Bone-Graft Substitutes, Hemostatic Agents, Surgical Sealants and Adhesives, Soft-Tissue Attachments, Adhesion Barriers, And Staple Line Reinforcement are the products included in the Biosurgery market report. What is the overall market value of the biosurgery market report? The Global Biosurgery Market share was USD 15.08 billion in 2020 and is predicted to reach USD 26.25 billion by 2030 with a CAGR of 5.7 percent. Which is the base year computed in the biosurgery market report? The Biosurgery Market forecast base year for the biosurgery market report is 2020. What are the key Biosurgery Market trends? The Biosurgery Market analysis presents a rising focus on effective blood loss management and growth in the size of elective surgeries, increasing prevalence of lifestyle disorders and chronic diseases, and rising geriatric population as the key trends. What is the Biosurgery Market size? The Global Biosurgery Market size was USD 15.93 billion in 2021. Which are the industry players in the global biosurgery market? Johnson & Johnson (Ethicon) Strykers, Medtronic Plc, Baxter International, Sanofi, Pfizer, , C.R. Bard, B. Braun Melsungen AG, & Integra Lifesciences Corporation are the major industry players in the biosurgery market. Sources: https://www.cdc.gov/nchs/data/nhsr/nhsr102.pdf https://www.ncbi.nlm.nih.gov/books/NBK535393/ https://apps.who.int/iris/bitstream/handle/10665/332070/9789240005105-eng.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388795/ https://www.health-tourism.com/medical-tourism/statistics/ https://www.cureus.com/articles/66182-impact-of-the-covid-19-outbreak-on-orthopedic-surgery-a-nationwide-analysis-of-the-first-pandemic-year https://link.springer.com/article/10.1007/s00268-020-05794-7 https://stanfordhealthcare.org/medical-clinics/surgery-clinic/patient-resources/surgery-statistics.html https://www.ruralhealthinfo.org/toolkits/aging/1/demographics\ https://www.investegate.co.uk/tissue-regenix-group/rns/launch-of-dermapure--meshed-and-vnewtm/202109010700102897K/ https://www.businesswire.com/news/home/20210428005356/en/Aroa-Biosurgery-Launches-New-Product-Myriad-Morcells%E2%84%A2---Offering-Highly-Conformable-Tissue-Regeneration-in-Wound-Beds---Following-Recent-FDA-Clearance https://investors.bd.com/news-releases/news-release-details/bd-completes-acquisition-straub-medical https://ir.orthofix.com/press-releases/news-details/2020/Orthofix-Launches-O-GENESIS-Graft-Delivery-System-and-New-Hydrated-Ready-to-Use-AlloQuent-Structural-Allograft-Q-PACK/default.aspx https://investor.baxter.com/investors/events-and-news/news/press-release-details/2020/Baxter-Launches-Peri-Strips-Dry-With-Secure-Grip-Technology-for-Reliable-Staple-Line-Reinforcement-in-Surgical-Procedures/default.aspx 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Biosurgery Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Biosurgery Market 4.2.1 Market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 Market, by region, 2021 - 2030 (USD Million) 4.4 By Route of Product Type Business Analysis 4.4.1 Market, By Route of Product Type, 2021 - 2030 (USD Million) 4.5 By Surgery Business Analysis 4.5.1 Market, By Surgery, 2021 - 2030 (USD Million) 4.6 Origin Business Analysis 4.6.1 Market, By Origin, 2021 - 2030 (USD Million) 4.6 End-user Business Analysis 4.6.1 Market, By End-user, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 Market PEST analysis 4.9.2 Market Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On the Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. End-user Analysis 5.11.1. Trends in End-user (2014-2021) 5.11.2. Trends in End-user (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Route of Product Type 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Route of Product Type Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Bone-Graft Substitutes 7.3.1. Bone-Graft Substitutes market, 2021 - 2030 (USD Million) 7.4. Soft-Tissue Attachments 7.4.1. Soft-Tissue Attachments market, 2021 - 2030 (USD Million) 7.5. Hemostatic Agents 7.5.1. Hemostatic Agents market, 2021 - 2030 (USD Million) 7.6. Surgical Sealants and Adhesives 7.6.1. Surgical Sealants and Adhesives market, 2021 - 2030 (USD Million) 7.7. Adhesion Barriers 7.7.1. Adhesion Barriers market, 2021 - 2030 (USD Million) 7.8. Staple-Line Reinforcement Agents 7.8.1. Staple-Line Reinforcement Agents market, 2021 - 2030 (USD Million) 7.9. Others 7.9.1. Others market, 2021 - 2030 (USD Million) 8. Market: By Surgery Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Orthopedic 8.3.1. Orthopedic market, 2021 - 2030 (USD Million) 8.4. General 8.4.1. General market, 2021 - 2030 (USD Million) 8.5. Neurological 8.5.1. Neurological market, 2021 - 2030 (USD Million) 8.6. Cardiovascular 8.6.1. Cardiovascular market, 2021 - 2030 (USD Million) 8.7. Reconstructive 8.7.1. Reconstructive market, 2021 - 2030 (USD Million) 8.8. Gynecological 8.8.1. Gynecological market, 2021 - 2030 (USD Million) 8.9. Urological 8.9.1. Urological market, 2021 - 2030 (USD Million) 8.10. Thoracic 8.10.1. Thoracic market, 2021 - 2030 (USD Million) 9. Market: By Origin Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Biological 9.3.1. Biological market, 2021 - 2030 (USD Million) 9.4. Synthetic 9.4.1. Synthetic market, 2021 - 2030 (USD Million) 10. Market: By End-user Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Hospitals 10.3.1. Hospitals market, 2021 - 2030 (USD Million) 10.4. Clinics 10.4.1. Clinics market, 2021 - 2030 (USD Million) 10.5. Ambulatory Surgery Centers/Clinics 10.5.1. Ambulatory Surgery Centers/Clinics market, 2021 - 2030 (USD Million) 10.6. Others 10.6.1. Others market, 2021 - 2030 (USD Million) 11. Market: Regional Outlook 11.1 North America 11.1.1. North America market, By Route of Product Type, 2021 - 2030 (USD Million) 11.1.2. North America market, By Surgery, 2021 - 2030 (USD Million) 11.1.3. North America market, by End-user, 2021 - 2030 (USD Million) 11.1.4. North America market, by Country, 2021 - 2030 (USD Million) 11.1.4.1. U.S. 11.1.4.1.1. U.S. market, By Route of Product Type, 2021 - 2030 (USD Million) 11.1.4.1.2. U.S. market, By Surgery, 2021 - 2030 (USD Million) 11.1.4.1.3. U.S. market, by End-user, 2021 - 2030 (USD Million) 11.1.4.2. Canada 11.1.4.2.1. Canada market, By Route of Product Type, 2021 - 2030 (USD Million) 11.1.4.2.2. Canada market, By Surgery, 2021 - 2030 (USD Million) 11.1.4.2.3. Canada market, by End-user, 2021 - 2030 (USD Million) 11.2. Europe 11.2.1. Europe market, By Route of Product Type, 2021 - 2030 (USD Million) 11.2.2. Europe market, By Surgery, 2021 - 2030 (USD Million) 11.2.3. Europe market, by End-user, 2021 - 2030 (USD Million) 11.2.4. Europe market, by country, 2021 - 2030 (USD Million) 11.2.4.1 U.K. 11.2.4.1.1. U.K. market, By Route of Product Type, 2021 - 2030 (USD Million) 11.2.4.1.2. U.K. market, By Surgery, 2021 - 2030 (USD Million) 11.2.4.1.3. U.K. market, by End-user, 2021 - 2030 (USD Million) 11.2.4.2. Germany 11.2.4.2.1. Germany market, By Route of Product Type, 2021 - 2030 (USD Million) 11.2.4.2.2. Germany market, By Surgery, 2021 - 2030 (USD Million) 11.2.4.2.3. Germany market, by End-user, 2021 - 2030 (USD Million) 11.2.4.3. France 11.2.4.3.1. France market, By Route of Product Type, 2021 - 2030 (USD Million) 11.2.4.3.2. France market, By Surgery, 2021 - 2030 (USD Million) 11.2.4.3.3. France market, by End-user, 2021 - 2030 (USD Million) 11.2.4.4. Rest of Europe 11.2.4.4.1. Rest of Europe market, By Route of Product Type, 2021 - 2030 (USD Million) 11.2.4.4.2. Rest of Europe market, By Surgery, 2021 - 2030 (USD Million) 11.2.4.4.3. Rest of Europe market, by End-user, 2021 - 2030 (USD Million) 11.3. Asia Pacific 11.3.1. Asia Pacific market, By Route of Product Type, 2021 - 2030 (USD Million) 11.3.2. Asia Pacific market, By Surgery, 2021 - 2030 (USD Million) 11.3.3. Asia Pacific market, by End-user, 2021 - 2030 (USD Million) 11.3.4. Asia Pacific market, by country, 2021 - 2030 (USD Million) 11.3.4.1. China 11.3.4.1.1. China market, By Route of Product Type, 2021 - 2030 (USD Million) 11.3.4.1.2. China market, By Surgery, 2021 - 2030 (USD Million) 11.3.4.1.3. China market, by End-user, 2021 - 2030 (USD Million) 11.3.4.2. India 11.3.4.2.1. India market, By Route of Product Type, 2021 - 2030 (USD Million) 11.3.4.2.2. India market, By Surgery, 2021 - 2030 (USD Million) 11.3.4.2.3. India market, by End-user, 2021 - 2030 (USD Million) 11.3.4.3. Japan 11.3.4.3.1. Japan market, By Route of Product Type, 2021 - 2030 (USD Million) 11.3.4.3.2. Japan market, By Surgery, 2021 - 2030 (USD Million) 11.3.4.3.3. Japan market, by End-user, 2021 - 2030 (USD Million) 11.3.4.4. South Korea 11.3.4.4.1. South Korea market, By Route of Product Type, 2021 - 2030 (USD Million) 11.3.4.4.2. South Korea market, By Surgery, 2021 - 2030 (USD Million) 11.3.4.4.3. South Korea market, by End-user, 2021 - 2030 (USD Million) 11.3.4.5. Rest of ASIA PACIFIC 11.3.4.5.1. Rest of ASIA PACIFIC market, By Route of Product Type, 2021 - 2030 (USD Million) 11.3.4.5.2. Rest of ASIA PACIFIC market, By Surgery, 2021 - 2030 (USD Million) 11.3.4.5.3. Rest of ASIA PACIFIC market, by End-user, 2021 - 2030 (USD Million) 11.4. Latin America 11.4.1. Latin America market, By Route of Product Type, 2021 - 2030 (USD Million) 11.4.2. Latin America market, By Surgery, 2021 - 2030 (USD Million) 11.4.3. Latin America market, by End-user, 2021 - 2030 (USD Million) 11.4.4. Latin America market, by country, 2021 - 2030 (USD Million) 11.4.4.1. Brazil 11.4.4.1.1. Brazil market, By Route of Product Type, 2021 - 2030 (USD Million) 11.4.4.1.2. Brazil market, By Surgery, 2021 - 2030 (USD Million) 11.4.4.1.3. Brazil market, by End-user, 2021 - 2030 (USD Million) 11.4.4.2. Mexico 11.4.4.2.1. Mexico market, By Route of Product Type, 2021 - 2030 (USD Million) 11.4.4.2.2. Mexico market, By Surgery, 2021 - 2030 (USD Million) 11.4.4.2.3. Mexico market, by End-user, 2021 - 2030 (USD Million) 11.4.4.3. Rest of the Latin America 11.4.4.3.1. Rest of the Latin America market, By Route of Product Type, 2021 - 2030 (USD Million) 11.4.4.3.2. Rest of the Latin America market, By Surgery, 2021 - 2030 (USD Million) 11.4.4.3.3. Rest of the Latin America market, by End-user, 2021 - 2030 (USD Million) 11.5. MEA 11.5.1. MEA market, By Route of Product Type, 2021 - 2030 (USD Million) 11.5.2. MEA market, By Surgery, 2021 - 2030 (USD Million) 11.5.3. MEA market, by End-user, 2021 - 2030 (USD Million) 11.5.4. MEA market, by Region, 2021 - 2030 (USD Million) 12. Competitive Landscape 12.1 Johnson & Johnson 12.1.1. Company overview 12.1.2. Financial performance 12.1.3. Route of Product Type Portfolio Analysis 12.1.4. Business Strategy & Recent Development 12.2. Baxter International Inc. 12.2.1. Company overview 12.2.2. Financial performance 12.2.3. Route of Product Type Portfolio Analysis 12.2.4. Business Strategy & Recent Development 12.3. Medtronic Plc 12.3.1. Company overview 12.3.2. Financial performance 12.3.3. Route of Product Type Portfolio Analysis 12.3.4. Business Strategy & Recent Development 12.4. Becton, Dickinson & Co. 12.4.1. Company overview 12.4.2. Financial performance 12.4.3. Route of Product Type Portfolio Analysis 12.4.4. Business Strategy & Recent Development 12.5. B. Braun Melsungen AG 12.5.1. Company overview 12.5.2. Financial performance 12.5.3. Route of Product Type Portfolio Analysis 12.5.4. Business Strategy & Recent Development 12.6. Stryker Corp. 12.6.1. Company overview 12.6.2. Financial performance 12.6.3. Route of Product Type Portfolio Analysis 12.6.4. Business Strategy & Recent Development 12.7. Integra Lifesciences Holdings Corp. 12.7.1. Company overview 12.7.2. Financial performance 12.7.3. Route of Product Type Portfolio Analysis 12.7.4. Business Strategy & Recent Development 12.8. CSL Ltd. 12.8.1. Company overview 12.8.2. Financial performance 12.8.3. Route of Product Type Portfolio Analysis 12.8.4. Business Strategy & Recent Development 12.9. Hemostasis L.L.C. 12.9.1. Company overview 12.9.2. Financial performance 12.9.3. Route of Product Type Portfolio Analysis 12.9.4. Business Strategy & Recent Development 12.10. Pfizer Inc. 12.10.1. Company overview 12.10.2. Financial performance 12.10.3. Route of Product Type Portfolio Analysis 12.10.4. Business Strategy & Recent Development 12.11. Cyrolife Inc. 12.11.1. Company overview 12.11.2. Financial performance 12.11.3. Route of Product Type Portfolio Analysis 12.11.4. Business Strategy & Recent Development 12.12. Zimmer Biomet 12.12.1. Company overview 12.12.2. Financial performance 12.12.3. Route of Product Type Portfolio Analysis 12.12.4. Business Strategy & Recent Development 12.13. Kuros Biosciences AG 12.13.1. Company overview 12.13.2. Financial performance 12.13.3. Route of Product Type Portfolio Analysis 12.13.4. Business Strategy & Recent Development 12.14. Orthofix Medical Inc. 12.14.1. Company overview 12.14.2. Financial performance 12.14.3. Route of Product Type Portfolio Analysis 12.14.4. Business Strategy & Recent Development 12.15. Smiths & Nephew Plc. 12.15.1. Company overview 12.15.2. Financial performance 12.15.3. Route of Product Type Portfolio Analysis 12.15.4. Business Strategy & Recent Development 12.16. Smiths & Nephew Plc. 12.16.1. Company overview 12.16.2. Financial performance 12.16.3. Route of Product Type Portfolio Analysis 12.16.4. Business Strategy & Recent Development 12.17. Ecm biosurgery 12.17.1. Company overview 12.17.2. Financial performance 12.17.3. Route of Product Type Portfolio Analysis 12.17.4. Business Strategy & Recent Development 12.18. Genzyme biosurgery 12.18.1. Company overview 12.18.2. Financial performance 12.18.3. Route of Product Type Portfolio Analysis 12.18.4. Business Strategy & Recent Development List of Tables (85 Tables) TABLE 1. MARKET, By Route of Product Type, 2021-2030 (USD Million) TABLE 2. MARKET FOR Bone-Graft Substitutes, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Soft-Tissue Attachments, BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Hemostatic Agents, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Surgical Sealants and Adhesives, BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET FOR Adhesion Barriers, BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET FOR Staple-Line Reinforcement Agents, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET, By Surgery, 2021-2030 (USD Million) TABLE 11. MARKET FOR Orthopedic, BY REGION, 2021-2030 (USD Million) TABLE 12. MARKET FOR General, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET FOR Neurological, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Cardiovascular, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET FOR Reconstructive, BY REGION, 2021-2030 (USD Million) TABLE 16. MARKET FOR Gynecological, BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET FOR Urological, BY REGION, 2021-2030 (USD Million) TABLE 18. MARKET FOR Thoracic, BY REGION, 2021-2030 (USD Million) TABLE 19. MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 20. MARKET FOR Hospitals, BY REGION, 2021-2030 (USD Million) TABLE 21. MARKET FOR Clinics, BY REGION, 2021-2030 (USD Million) TABLE 22. MARKET FOR Ambulatory Surgery Centers/Clinics, BY REGION, 2021-2030 (USD Million) TABLE 23. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 24. MARKET, By Origin, 2021-2030 (USD Million) TABLE 25. MARKET FOR Biological, BY REGION, 2021-2030 (USD Million) TABLE 26. MARKET FOR Synthetic, BY REGION, 2021-2030 (USD Million) TABLE 27. MARKET FOR Dendrimer, BY REGION, 2021-2030 (USD Million) TABLE 28. MARKET FOR Nanoparticle, BY REGION, 2021-2030 (USD Million) TABLE 29. MARKET FOR Liposome, BY REGION, 2021-2030 (USD Million) TABLE 30. MARKET FOR Scaffold, BY REGION, 2021-2030 (USD Million) TABLE 31. MARKET FOR Mesoporous Material, BY REGION, 2021-2030 (USD Million) TABLE 32. MARKET FOR Niosomes, BY REGION, 2021-2030 (USD Million) TABLE 33. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 34. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 35. NORTH AMERICA MARKET, By Route of Product Type, 2021-2030 (USD Million) TABLE 36. NORTH AMERICA MARKET, By Surgery, 2021-2030 (USD Million) TABLE 37. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 38. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 39. EUROPE MARKET, By Route of Product Type, 2021-2030 (USD Million) TABLE 40. EUROPE MARKET, By Surgery, 2021-2030 (USD Million) TABLE 41. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 42. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 43. ASIA-PACIFIC MARKET, By Route of Product Type, 2021-2030 (USD Million) TABLE 44. ASIA-PACIFIC MARKET, By Surgery, 2021-2030 (USD Million) TABLE 45. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 46. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 47. LAMEA MARKET, By Route of Product Type, 2021-2030 (USD Million) TABLE 48. LAMEA MARKET, By Origin, 2021-2030 (USD Million) TABLE 49. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 50. Johnson & Johnson: COMPANY SNAPSHOT TABLE 51. Johnson & Johnson: OPERATING SEGMENTS TABLE 52. Baxter International Inc.: COMPANY SNAPSHOT TABLE 53. Baxter International Inc.: OPERATING SEGMENTS TABLE 54. Medtronic Plc: COMPANY SNAPSHOT TABLE 55. Medtronic Plc: OPERATING SEGMENTS TABLE 56. Becton, Dickinson & Co.: COMPANY SNAPSHOT TABLE 57. Becton, Dickinson & Co.: OPERATING SEGMENTS TABLE 58. B. Braun Melsungen AG: COMPANY SNAPSHOT TABLE 59. B. Braun Melsungen AG: OPERATING SEGMENTS TABLE 60. Stryker Corp.: COMPANY SNAPSHOT TABLE 61. Stryker Corp.: OPERATING SEGMENTS TABLE 62. Integra Lifesciences Holdings Corp.: COMPANY SNAPSHOT TABLE 63. Integra Lifesciences Holdings Corp.: OPERATING SEGMENTS TABLE 64. CSL Ltd.: COMPANY SNAPSHOT TABLE 65. CSL Ltd.: OPERATING SEGMENTS TABLE 66. Hemostasis L.L.C.: COMPANY SNAPSHOT TABLE 67. Hemostasis L.L.C.: OPERATING SEGMENTS TABLE 68. Pfizer Inc.: COMPANY SNAPSHOT TABLE 69. Pfizer Inc.: OPERATING SEGMENTS TABLE 70. Cyrolife Inc.: COMPANY SNAPSHOT TABLE 71. Cyrolife Inc.: OPERATING SEGMENTS TABLE 72. Zimmer Biomet: COMPANY SNAPSHOT TABLE 73. Zimmer Biomet: OPERATING SEGMENTS TABLE 74. Kuros Biosciences AG: COMPANY SNAPSHOT TABLE 75. Kuros Biosciences AG: OPERATING SEGMENTS TABLE 76. Orthofix Medical Inc.: COMPANY SNAPSHOT TABLE 77. Orthofix Medical Inc.: OPERATING SEGMENTS TABLE 78. Smiths & Nephew Plc.: COMPANY SNAPSHOT TABLE 79. Smiths & Nephew Plc.: OPERATING SEGMENTS TABLE 80. Smiths & Nephew Plc.: COMPANY SNAPSHOT TABLE 81. Smiths & Nephew Plc.: OPERATING SEGMENTS TABLE 82. Ecm biosurgery: COMPANY SNAPSHOT TABLE 83. Ecm biosurgery: OPERATING SEGMENTS TABLE 84. Genzyme biosurgery: COMPANY SNAPSHOT TABLE 85. Genzyme biosurgery: OPERATING SEGMENTS List of Figures (23 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Route of Product Type-Based Estimation Figure 6 Top 18 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Biosurgery Market, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Biosurgery Market, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Surgery, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By End-user, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Route of Product Type, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Origin, 2019 vs. 2025 (USD Million) Figure 15 Geographical Snapshot of the Market Figure 16 Bone-Graft Substitutes to Witness Higher CAGR in Market for Route of Product Type Segment during Forecast Period. Figure 17 Hospitals to Witness Higher CAGR in Market for End-user Segment during Forecast Period. Figure 18 General surgery to Witness Higher CAGR in the Market for Surgery Segment during Forecast Period. Figure 19 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2020 Figure 20 Market: Drivers, Restraints, Opportunities, and Challenges Figure 21 North America: Market Snapshot Figure 22 Asia Pacific: Market Snapshot Figure 23 Vendor Dive: Evaluation Overview